High prevalence of BRCA1 deletions in BRCAPRO-positive patients with high carrier probability

S. Veschi, G. Aceto, A. P. Scioletti, V. Gatta, G. Palka, A. Cama, R. Mariani-Costantini, P. Battista, V. Calò, F. Barbera, V. Bazan, A. Russo, L. Stuppia

Research output: Contribution to journalArticlepeer-review


Mutation screening of the BRCA1 and BRCA2 genes in probands with familial breast/ovarian cancer has been greatly improved by the multiplex ligation-dependent probe amplification (MLPA) assay able to evidence gene rearrangements not detectable by standard screening methods. However, no criteria for selection of cases to be submitted to the MLPA test have been reported yet. We used the BRCAPro software for the selection of familial breast/ovarian cancer probands investigated with the MLPA approach after negative BRCA1/2 conventional mutation screening. One hundred and seventy-seven probands were investigated for germline BRCA1/2 mutations after assessment of genetic risk using BRCAPro. Probands were classified as BRCAPro positive (n = 67) when the carrier probability (CP) was >10% and as BRCAPro negative (n = 110), when the CP was 50%.

Original languageEnglish
JournalAnnals of Oncology
Issue numberSUPPL. 6
Publication statusPublished - Jun 2007


  • BRCA1
  • BRCA2
  • BRCAPro
  • Breast cancer
  • MLPA
  • Ovarian cancer

ASJC Scopus subject areas

  • Oncology
  • Hematology
  • Cancer Research


Dive into the research topics of 'High prevalence of BRCA1 deletions in BRCAPRO-positive patients with high carrier probability'. Together they form a unique fingerprint.

Cite this